What the Latest Dementia Study Says about Links with Certain Medicines

POSTED ON: June 12, 2022

Controversy regarding the purported link between the use of proton pump inhibitors (PPIs) or histamine H2 receptor antagonists (H2RAs) and risk for dementia continues.

What the Latest Dementia Study Says about Links with Certain Medicines

MedScape’s recent article entitled “More Evidence Dementia Not Linked to PPI Use in Older People” reports that among nearly 19,000 people, no link was found between the use of proton pump inhibitors (PPIs) or histamine H2 receptor antagonists (H2Ras) and a greater likelihood of incident dementia, Alzheimer’s disease, or cognitive decline in people older than 65 years.

“We found that baseline PPI or H2RA use in older adults was not associated with dementia, with mild cognitive impairment, or declines in cognitive scores over time,” said lead author Raaj Shishir Mehta, MD, a gastroenterology fellow at Massachusetts General Hospital in Boston.

“While deprescribing efforts are important, especially when medications are not indicated, these data provide reassurance about the cognitive impacts of long-term use of PPIs in older adults,” he added.

As PPI use has increased worldwide, so too have concerns over the adverse effects from their long-term use, Mehta said.

“One particular area of concern, especially among older adults, is the link between long-term PPI use and risk for dementia,” he said.

Behind the controversy was a February 2016 study published in JAMA Neurology that showed a positive connection between PPI use and dementia in residents of Germany aged 75 years and older.

The researchers linked PPI use to a 44% increased risk of dementia a five-year period.

This study was based on claims data, which can introduce “inaccuracy or bias in defining dementia cases,” Dr. Mehta said. He commented that it and other previous studies also were limited by an inability to account for concomitant medications or comorbidities.

To overcome these limitations in their study, Dr. Mehta and colleagues examined medication data collected during in-person visits and asked experts to confirm dementia outcomes.

The research data come from ASPREE, a large aspirin study of 18,846 people 65+ in the United States and Australia. Participants were enrolled from 2010 to 2014, and a total of 566 people developed incident dementia during follow-up.

The researchers had data on alcohol consumption and other lifestyle factors, along with data on comorbidities, hospitalizations and overall well-being.

BOOK A CALL with me, Ted Vicknair, Board Certified Estate Planning and Administration Specialist, Board Certified Tax Law Specialist, and CPA to learn more about estate planning, incapacity planning, and asset protection.

If you liked this article, “What the Latest Dementia Study Says about Links with Certain Medicines” read also these additional articles: What Fruit Is Best for My Heart? and How to Get Into a Nursing Home as a Medicaid Recipient and What are the Most Important Estate Planning Documents for Seniors? and Can My Hands Tell Me about Liver Problems?

Reference: MedScape (May 24, 2022) “More Evidence Dementia Not Linked to PPI Use in Older People”

Success Stories